menu

Loading...

GENB Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

13.950

Open

12.300

VWAP

13.11

Vol

761.14K

Mkt Cap

1.61B

Low

12.300

Amount

9.98M

EV/EBITDA(TTM)

--

Total Shares

127.45M

EV

--

EV/OCF(TTM)

--

P/S(TTM)

--

Events Timeline

(ET)

2026-03-02

11:30:00

New

Generate Biomedicines Debuts with 6% Price Increase

2026-02-27 (ET)

2026-02-27

13:00:00

Generate Biomedicines Prices 25M Shares at $16.00

2026-02-27

12:40:00

Generate Biomedicines Prices 25M Shares at $16.00

2026-02-27

05:40:00

Goldman Sachs and Morgan Stanley Jointly Manage IPO, Pricing at Midpoint of $16

News

renaissancecapital

14:09 PMrenaissancecapital

February IPO Market Review and Outlook

renaissancecapital

02-27renaissancecapital

Generate Biomedicines Announces IPO Terms for $400 Million Raise

renaissancecapital

02-27renaissancecapital

Generate Biomedicines Plans $400 Million IPO Amid February Market Lull

renaissancecapital

02-27renaissancecapital

Generate Biomedicines Raises $400 Million in IPO for AI-Driven Therapies

0 Analyst Rating

Wall Street analysts forecast GENB stock price to rise

0 Buy

0 Hold

0 Sell

Current: 0.000

Low

Averages

High

Current: 0.000

Low

Averages

High

No data

No data

Valuation Metrics

The current forward P/E ratio for Generate Biomedicines, Inc. (GENB.O) is --, compared to its 5-year average forward P/E of --. For a more detailed relative valuation and DCF analysis to assess Generate Biomedicines, Inc.'s fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

5Y Average PE

Current PE

NaN

Overvalued PE

Undervalued PE

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

5Y Average EV/EBITDA

Current EV/EBITDA

NaN

Overvalued EV/EBITDA

Undervalued EV/EBITDA

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

Current PS

NaN

Overvalued PS

Undervalued PS

Financials

AI Analysis

Annual

Quarterly

Whales Holding GENB

Trading Trends

People Also Watch

Frequently Asked Questions

What is Generate Biomedicines, Inc. (GENB) stock price today?

The current price of GENB is 13.09 USD — it has increased 3.48

What is Generate Biomedicines, Inc. (GENB)'s business?

What is the price predicton of GENB Stock?

Wall Street analysts forecast GENB stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for GENB is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Generate Biomedicines, Inc. (GENB)'s revenue for the last quarter?

Generate Biomedicines, Inc. revenue for the last quarter amounts to NaN USD, decreased

What is Generate Biomedicines, Inc. (GENB)'s earnings per share (EPS) for the last quarter?

Generate Biomedicines, Inc.. EPS for the last quarter amounts to USD, decreased

How many employees does Generate Biomedicines, Inc. (GENB). have?

Generate Biomedicines, Inc. (GENB) has 0 emplpoyees as of March 02 2026.

What is Generate Biomedicines, Inc. (GENB) market cap?

Today GENB has the market capitalization of 1.61B USD.